| 臺大學術典藏 |
2021-02-18T01:45:21Z |
A Multicenter Phase II Study of Second-Line Axitinib for Patients with Advanced Hepatocellular Carcinoma Failing First-Line Sorafenib Monotherapy
|
Lin Z.-Z.;Chen B.-B.;Hung Y.-P.;Huang P.-H.;Shen Y.-C.;Shao Y.-Y.;Chiun Hsu;Cheng A.-L.;Lee R.-C.;Chao Y.; Lin Z.-Z.; Chen B.-B.; Hung Y.-P.; Huang P.-H.; Shen Y.-C.; Shao Y.-Y.; Chiun Hsu; Cheng A.-L.; Lee R.-C.; Chao Y. |
| 臺大學術典藏 |
2021-02-18T01:45:20Z |
Safety and Preliminary Efficacy of Ramucirumab in Combination with FOLFOX4 in Patients with Advanced Hepatocellular Carcinoma: A Nonrandomized, Open-Label, Phase Ib Study
|
Lin C.-C.;Yang T.-S.;Yen C.-J.;Cheng R.;Liu J.;Chiun Hsu; Lin C.-C.; Yang T.-S.; Yen C.-J.; Cheng R.; Liu J.; Chiun Hsu |
| 臺大學術典藏 |
2021-02-18T01:45:20Z |
Multicentre, phase II study of gemcitabine and S-1 in patients with advanced biliary tract cancer: TG1308 study
|
Chiang N.-J.;Chen M.-H.;Yang S.-H.;Chiun Hsu;Yen C.-J.;Tsou H.-H.;Su Y.-Y.;Chen J.-S.;Shan Y.-S.;Chen L.-T.; Chiang N.-J.; Chen M.-H.; Yang S.-H.; Chiun Hsu; Yen C.-J.; Tsou H.-H.; Su Y.-Y.; Chen J.-S.; Shan Y.-S.; Chen L.-T. |
| 臺大學術典藏 |
2021-01-18T09:11:58Z |
The unique characteristic in peripheral immune cells in patients with advanced hepatocellular carcinoma
|
YI-PING HUNG; YU-YUN SHAO; Chiun Hsu; CHIH-HUNG HSU; Lee, Jan Mou; Yang, Muh Hwa; Chao, Yee |
| 臺大學術典藏 |
2021 |
Management consensus guideline for hepatocellular carcinoma: 2020 update on surveillance, diagnosis, and systemic treatment by the Taiwan Liver Cancer Association and the Gastroenterological Society of Taiwan
|
Tseng J.-H.; Ho M.-C.; Liao L.-Y.; Liang J.-D.; Wang C.-K.; Lee W.-C.; Shao Y.-Y.; Wang S.-Y.; Lin S.-M.; Chen K.-Y.; Lee R.-C.; Liang P.-C.; Huang K.-W.; Hu J.-T.; Kee K.-M.; Lin C.-L.; Lu S.-N.; Wang J.-H.; Chen C.-H.; Liu C.-J.; Huang Y.-H.; Wang C.-C.; Wang T.-E.; Chuang P.-H.; Dai C.-Y.; CHIUN HSU; Chen S.-C.; Hsieh C.-H.; Diagnosis Group, Systemic Therapy Group |
| 臺大學術典藏 |
2020-08-14T01:27:01Z |
Development of a PD-L1-Expressing Orthotopic Liver Cancer Model: Implications for Immunotherapy for Hepatocellular Carcinoma
|
Ou, Da-Liang;Lin, Yu-Yang;Hsu, Chia-Lang;Lin, Yin-Yao;Chen, Chia-Wei;Yu, Jhang-Sian;Shi-Chuen Miaw;Hsu, Ping-Ning;Cheng, Ann-Lii;Chiun Hsu; Ou, Da-Liang; Lin, Yu-Yang; Hsu, Chia-Lang; Lin, Yin-Yao; Chen, Chia-Wei; Yu, Jhang-Sian; SHI-CHUEN MIAW; Hsu, Ping-Ning; Cheng, Ann-Lii; Chiun Hsu |
| 臺大學術典藏 |
2020-04-10T12:51:33Z |
Surgical resection for recurrent hepatocellular carcinoma: Prognosis and analysis of risk factors
|
Hu R.-H.;Lee P.-H.;Yu S.-C.;Dai H.-C.;Sheu J.-C.;Lai M.-Y.;Chiun Hsu;Chen D.-S.; Hu R.-H.; Lee P.-H.; Yu S.-C.; Dai H.-C.; Sheu J.-C.; Lai M.-Y.; Chiun Hsu; Chen D.-S. |
| 臺大學術典藏 |
2020-04-10T12:51:32Z |
Comparison of MALT and non-MALT primary large cell lymphoma of the stomach: Does histologic evidence of MALT affect chemotherapy response?
|
Chiun Hsu;Chen C.-L.;Chen L.-T.;Liu H.-T.;Chen Y.-C.;Jan C.-M.;Liu C.-S.;Cheng A.-L.; Chiun Hsu; Chen C.-L.; Chen L.-T.; Liu H.-T.; Chen Y.-C.; Jan C.-M.; Liu C.-S.; Cheng A.-L. |
| 臺大學術典藏 |
2020-04-10T12:51:32Z |
Chemotherapy alone versus, surgery followed by chemotherapy for stage I/IIE large-cell lymphoma of the stomach
|
Cheng A.-L.; Chen Y.-C.; Chen L.-T.; Chiang I.-P.; Chen C.-L.; Chiun Hsu; Liu H.-T.; Liu H.-T.;Chiun Hsu;Chen C.-L.;Chiang I.-P.;Chen L.-T.;Chen Y.-C.;Cheng A.-L. |
| 臺大學術典藏 |
2020-04-10T12:51:32Z |
Allogeneic stem cell transplantation for patients with high-risk myelodysplastic syndrome
|
Chiun Hsu;Lin M.-T.;Tang J.-L.;Tien H.-F.;Wang C.-H.;Chen Y.-C.; Chiun Hsu; Lin M.-T.; Tang J.-L.; Tien H.-F.; Wang C.-H.; Chen Y.-C. |
| 臺大學術典藏 |
2020-04-10T12:51:32Z |
Cisplatin, etoposide, and weekly high-dose 5-fluorouracil and leucovorin infusion (PE-HDFL) - A very effective regimen with good patients' compliance for advanced gastric cancer
|
Liu M.-Y.;Chiun Hsu;Lin J.-T.;Yeh K.-H.;Cheng A.-L.; Cheng A.-L.; Yeh K.-H.; Lin J.-T.; Chiun Hsu; Liu M.-Y. |
| 臺大學術典藏 |
2020-04-10T12:51:32Z |
MVP (mitomycin-C, vinblastine, cisplatin) salvage chemotherapy for relapsed and refractory metastatic breast cancer
|
Chiun Hsu; Yeh K.-H.; Hong R.-L.; Yang C.-H.; Lin M.-T.; Chen Y.-C.; Cheng A.-L.; Chiun Hsu;Yeh K.-H.;Hong R.-L.;Yang C.-H.;Lin M.-T.;Chen Y.-C.;Cheng A.-L. |
| 臺大學術典藏 |
2020-04-10T12:51:31Z |
HER-2/neu overexpression is rare in hepatocellular carcinoma and not predictive of anti-HER-2/neu regulation of cell growth and chemosensitivity
|
Chiun Hsu;Huang C.-L.;Hsu H.-C.;Lee P.-H.;Wang S.-J.;Cheng A.-L.; Chiun Hsu; Huang C.-L.; Hsu H.-C.; Lee P.-H.; Wang S.-J.; Cheng A.-L. |
| 臺大學術典藏 |
2020-04-10T12:51:31Z |
Gemcitabine and cisplatin in a multimodality treatment for locally advanced non-small cell lung cancer
|
Yang C.H.;Tsai C.M.;Wang L.S.;Lee Y.C.;Chang C.J.;Lui L.T.;Yen S.H.;Chiun Hsu;Cheng A.L.;Liu M.Y.;Chiang S.C.;Chen Y.M.;Luh K.T.;Huang M.H.;Yang P.-C.;Perng R.-P.; Perng R.-P.; Yang P.-C.; Luh K.T.; Huang M.H.; Chen Y.M.; Chiang S.C.; Liu M.Y.; Cheng A.L.; Chiun Hsu; Tsai C.M.; Wang L.S.; Lee Y.C.; Chang C.J.; Lui L.T.; Yen S.H.; Yang C.H. |
| 臺大學術典藏 |
2020-04-10T12:51:30Z |
Phase II trial combining paclitaxel with 24-hour infusion cisplatin for chemotherapy-naïve patients with locally advanced or metastatic breast carcinoma
|
Chiun Hsu;Huang C.-S.;Chao T.-Y.;Lu Y.-S.;Bu C.-F.;Chen M.M.;Chang K.-J.;Cheng A.-L.; Chiun Hsu; Huang C.-S.; Chao T.-Y.; Lu Y.-S.; Bu C.-F.; Chen M.M.; Chang K.-J.; Cheng A.-L. |
| 臺大學術典藏 |
2020-04-10T12:51:29Z |
Quality of life of lung cancer patients: Validation of the Taiwan Chinese version of the EORTC QLQ-C30 and QLQ-LC13
|
Chie W.-C.;Yang C.-H.;Chiun Hsu;Yang P.-C.; Chie W.-C.; Yang C.-H.; Chiun Hsu; Yang P.-C. |
| 臺大學術典藏 |
2020-04-10T12:51:29Z |
Phase II study of combination doxorubicin, interferon-α, and high-dose tamoxifen treatment for advanced hepatocellular carcinoma
|
Li C.-C.; Kuo S.-H.; Yeh K.-H.; Yang C.-H.; Hsu C.-H.; Wu C.-Y.; Cheng A.-L.; Lu Y.-S.;Chiun Hsu;Li C.-C.;Kuo S.-H.;Yeh K.-H.;Yang C.-H.;Hsu C.-H.;Wu C.-Y.;Cheng A.-L.; Lu Y.-S.; Chiun Hsu |
| 臺大學術典藏 |
2020-04-10T12:51:29Z |
Low-dose thalidomide treatment for advanced hepatocellular carcinoma
|
Yang P.-M.; Wu C.-Y.; Chen L.-T.; Chen C.-N.; Chiun Hsu; Chiun Hsu;Chen C.-N.;Chen L.-T.;Wu C.-Y.;Yang P.-M.;Lai M.-Y.;Lee P.-H.;Cheng A.-L.; Lai M.-Y.; Lee P.-H.; Cheng A.-L. |
| 臺大學術典藏 |
2020-04-10T12:51:28Z |
Effect of thalidomide in hepatocellular carcinoma: Assessment with power Doppler US and analysis of circulating angiogenic factors
|
Chiun Hsu;Chen C.-N.;Chen L.-T.;Wu C.-Y.;Hsieh F.-J.;Cheng A.-L.; Chiun Hsu; Chen C.-N.; Chen L.-T.; Wu C.-Y.; Hsieh F.-J.; Cheng A.-L. |
| 臺大學術典藏 |
2020-04-10T12:51:28Z |
Survival of stage IIIB/IV non-small cell lung cancer patients who received chemotherapy but did not participate in clinical trials
|
Kuo S.-H.;Yang C.-H.;Yu C.-J.;Chiun Hsu;Cheng A.-L.;Yang P.-C.; Kuo S.-H.; Yang C.-H.; Yu C.-J.; Chiun Hsu; Cheng A.-L.; Yang P.-C. |
| 臺大學術典藏 |
2020-04-10T12:51:28Z |
Lack of efficacy of troglitazone at clinically achievable concentrations, with or without 9-cis retinoic acid or cytotoxic agents, for hepatocellular carcinoma cell lines
|
Chen J.-Y.; Cheng A.-L.; Shen Y.-C.; Chiun Hsu; Shen Y.-C.;Chiun Hsu;Chen J.-Y.;Cheng A.-L. |
| 臺大學術典藏 |
2020-04-10T12:51:27Z |
Unexpected rapid progression of metastatic adenoid cystic carcinoma during treatment with imatinib mesylate
|
Lin C.-H.;Yen R.-F.;Jeng Y.-M.;Tzen C.-Y.;Chiun Hsu;Hong R.-L.; Lin C.-H.; Yen R.-F.; Jeng Y.-M.; Tzen C.-Y.; Chiun Hsu; Hong R.-L. |
| 臺大學術典藏 |
2020-04-10T12:51:27Z |
Gefitinib treatment for non-small cell lung cancer - A study including patients with poor performance status
|
Su W.-P.;Yang C.-H.;Yu C.-J.;Shih J.-Y.;Chiun Hsu;Yang P.-C.; Su W.-P.; Yang C.-H.; Yu C.-J.; Shih J.-Y.; Chiun Hsu; Yang P.-C. |
| 臺大學術典藏 |
2020-04-10T12:51:26Z |
Difference in the incidence trend of nasopharyngeal and oropharyngeal carcinomas in Taiwan: Implication from age-period-cohort analysis
|
Chiun Hsu;Shen Y.-C.;Cheng C.-C.;Hong R.-L.;Chang C.-J.;Cheng A.-L.; Chiun Hsu; Shen Y.-C.; Cheng C.-C.; Hong R.-L.; Chang C.-J.; Cheng A.-L. |
| 臺大學術典藏 |
2020-04-10T12:51:26Z |
Phase I-II trial of weekly gemcitabine plus high-dose 5-fluorouracil and leucovorin in advanced pancreatic cancer
|
Chen L.-T.; Shiah H.-S.;Cheng A.-L.;Chiun Hsu;Hsu C.-H.;Liu T.-W.;Chang J.-Y.;Jan C.-M.;Chao Y.;Yu W.-L.;Chuang T.-R.;Whang-Peng J.;Chen L.-T.; Shiah H.-S.; Cheng A.-L.; Chiun Hsu; Hsu C.-H.; Liu T.-W.; Chang J.-Y.; Jan C.-M.; Chao Y.; Yu W.-L.; Chuang T.-R.; Whang-Peng J. |
| 臺大學術典藏 |
2020-04-10T12:51:26Z |
Phase I study of biweekly gemcitabine followed by oxaliplatin and simplified 48-h infusion of fluorouracil/leucovorin for advanced pancreatic cancer
|
Ch'Ang H.-J.;Wang C.-C.;Cheng A.-L.;Chiun Hsu;Lu Y.-S.;Chang M.-C.;Lin J.-T.;Wang H.-P.;Shiah H.-S.;Liu T.-W.;Chang J.-Y.;Whang-Peng J.;Chen L.-T.; Ch'ang H.-J.; Wang C.-C.; Cheng A.-L.; Chiun Hsu; Lu Y.-S.; Chang M.-C.; Lin J.-T.; Wang H.-P.; Shiah H.-S.; Liu T.-W.; Chang J.-Y.; Whang-Peng J.; Chen L.-T. |
| 臺大學術典藏 |
2020-04-10T12:51:26Z |
CD24 expression is a prognostic factor in intrahepatic cholangiocarcinoma
|
Su M.-C.;Chiun Hsu;Kao H.-L.;Jeng Y.-M.; Su M.-C.; Chiun Hsu; Kao H.-L.; Jeng Y.-M. |
| 臺大學術典藏 |
2020-04-10T12:51:25Z |
Dynamic MRI signals in the second week of radiotherapy relate to treatment outcomes of hepatocellular carcinoma: A preliminary result
|
Liang P.-C.;Ch'Ang H.-J.;Chiun Hsu;Tseng S.S.;Shih T.T.F.;Wu Liu T.; Liang P.-C.; Ch'ang H.-J.; Chiun Hsu; Tseng S.S.; Shih T.T.F.; Wu Liu T. |
| 臺大學術典藏 |
2020-04-10T12:51:25Z |
Arsenic trioxide in patients with hepatocellular carcinoma: A phase II trial
|
Yang C.-H.; Cheng A.-L.; Lin C.-C.;Chiun Hsu;Hsu C.-H.;Hsu W.-L.;Cheng A.-L.;Yang C.-H.; Lin C.-C.; Chiun Hsu; Hsu C.-H.; Hsu W.-L. |
| 臺大學術典藏 |
2020-04-10T12:51:25Z |
Survival outcome and predictors of gefitinib antitumor activity in East Asian chemonaive patients with advanced nonsmall cell lung cancer
|
Gow C.-H.; Chiun Hsu; Chang G.-C.; Yang P.-C.; Su W.-P.; Lin C.-P.; Yang T.-Y.; Yu C.-J.; Chen K.-C.; Shih J.-Y.; Yang C.-H.; Yang C.-H.;Shih J.-Y.;Chen K.-C.;Yu C.-J.;Yang T.-Y.;Lin C.-P.;Su W.-P.;Gow C.-H.;Chiun Hsu;Chang G.-C.;Yang P.-C. |
| 臺大學術典藏 |
2020-04-10T12:51:24Z |
Comparison of hypoplastic myelodysplastic syndrome (MDS) with normo-/hypercellular MDS by International Prognostic Scoring System, cytogenetic and genetic studies
|
Tsay W.; Huang S.-Y.; Yao M.; Chen Y.-C.; Shen M.-C.; Wang C.-H.; Tien H.-F.; Chiun Hsu; Chen C.-Y.; Tang J.-L.; Ko B.-S.; Huang T.-C.; Huang T.-C.;Ko B.-S.;Tang J.-L.;Chiun Hsu;Chen C.-Y.;Tsay W.;Huang S.-Y.;Yao M.;Chen Y.-C.;Shen M.-C.;Wang C.-H.;Tien H.-F. |
| 臺大學術典藏 |
2020-04-10T12:51:24Z |
Molecular targeted therapy for advanced hepatocellular carcinoma
|
Shen Y.C.;Chiun Hsu;Cheng A.L.; Shen Y.C.; Chiun Hsu; Cheng A.L. |
| 臺大學術典藏 |
2020-04-10T12:51:24Z |
Multifractionated paclitaxel and cisplatin combined with 5-fluorouracil and leucovorin in patients with metastatic or recurrent esophageal squamous cell carcinoma
|
Yang C.-H.; Chiun Hsu; Tsai Y.-C.; Hsu W.-L.; Cheng A.-L.; Hsu C.-H.; Yeh K.-H.; Lin C.-C.; Lin C.-C.;Yeh K.-H.;Yang C.-H.;Chiun Hsu;Tsai Y.-C.;Hsu W.-L.;Cheng A.-L.;Hsu C.-H. |
| 臺大學術典藏 |
2020-04-10T12:51:23Z |
Weekly cisplatin, infusional high-dose 5-fluorouracil and leucovorin for advanced, recurrent and metastatic cervical carcinoma
|
Wei L.-H.; Hsieh C.-Y.; Lin H.-H.; Chiun Hsu; Chen C.-A.; Hsiao S.-M. |
| 臺大學術典藏 |
2020-04-10T12:51:23Z |
Outcome of advanced nonsmall cell lung cancer patients receiving gemcitabine and weekly paclitaxel as first-line treatment
|
Yang C.-H.; Yang P.-C.; Cheng A.-L.; Lin C.-C.; Hsu C.-H.; Yu C.-J.; Chang Y.-C.; Chiun Hsu; Lin Z.-Z. |
| 臺大學術典藏 |
2020-04-10T12:51:22Z |
Strategies to prevent hepatitis B virus reactivation in patients receiving immunosuppressive therapy
|
Wei S.-C.; Cheng A.-L.; Chen P.-J.; Chiun Hsu |
| 臺大學術典藏 |
2020-04-10T12:51:22Z |
Nuclear overexpression of mitotic regulatory proteins in biliary tract cancer: Correlation with clinicopathologic features and patient survival
|
Cheng A.-L.; Shen Y.-C.; Hu F.-C.; Jeng Y.-M.; Chang Y.-T.; Lin Z.-Z.; Chang M.-C.; Chiun Hsu |
| 臺大學術典藏 |
2020-04-10T12:51:22Z |
Gemcitabine plus conventional-dose epirubicin versus gemcitabine plus cisplatin as first-line chemotherapy for stage IIIB/IV non-small cell lung carcinoma-A randomized phase II trial
|
Huang T.-C.; Yang P.-C.; Yang C.-H.; Lin C.-C.; Chiun Hsu; Kuo S.-H.; Hu F.-C.; Cheng A.-L.; Shih J.-Y.; Yu C.-J. |
| 臺大學術典藏 |
2020-04-10T12:51:22Z |
Serum vascular endothelial growth factor/soluble vascular endothelial growth factor receptor 1 ratio is an independent prognostic marker in pancreatic cancer
|
Chang Y.-T.;Chang M.-C.;Wei S.-C.;Tien Y.-W.;Chiun Hsu;Liang P.-C.;Tsao P.-N.;Jan I.-S.;Wong J.-M.; Chang Y.-T.; Chang M.-C.; Wei S.-C.; Tien Y.-W.; Chiun Hsu; Liang P.-C.; Tsao P.-N.; Jan I.-S.; Wong J.-M. |
| 臺大學術典藏 |
2020-04-10T12:51:21Z |
Induction of Bim expression contributes to the antitumor synergy between sorafenib and mitogen-activated protein kinase/extracellular signal-regulated kinase kinase inhibitor CI-1040 in hepatocellular carcinoma
|
Ou D.-L.; Shen Y.-C.; Liang J.-D.; Liou J.-Y.; Yu S.-L.; Fan H.-H.; Wang D.-S.; Lu Y.-S.; Chiun Hsu; Cheng A.-L. |
| 臺大學術典藏 |
2020-04-10T12:51:21Z |
Lamivudine and hepatitis B reactivation
|
Chiun Hsu; Cheng A.-L.; Chen P.-J. |
| 臺大學術典藏 |
2020-04-10T12:51:21Z |
Bortezomib overcomes tumor necrosis factor-related apoptosis-inducing ligand resistance in hepatocellular carcinoma cells in part through the inhibition of the phosphatidylinositol 3-kinase/Akt pathway
|
Chen K.-F.; Yeh P.-Y.; Chiun Hsu; Hsu C.-H.; Lu Y.-S.; Hsieh H.-P.; Chen P.-J.; Cheng A.-L. |
| 臺大學術典藏 |
2020-04-10T12:51:21Z |
The Aurora kinase inhibitor VE-465 has anticancer effects in pre-clinical studies of human hepatocellular carcinoma
|
Lin Z.-Z.;Hsu H.-C.;Hsu C.-H.;Yeh P.-Y.;Huang C.-Y.F.;Huang Y.-F.;Chen T.-J.;Kuo S.-H.;Chiun Hsu;Hu F.-C.;Jeng Y.-M.;Chung Y.;Cheng A.-L.; Lin Z.-Z.; Hsu H.-C.; Hsu C.-H.; Yeh P.-Y.; Huang C.-Y.F.; Huang Y.-F.; Chen T.-J.; Kuo S.-H.; Chiun Hsu; Hu F.-C.; Jeng Y.-M.; Chung Y.; Cheng A.-L. |
| 臺大學術典藏 |
2020-04-10T12:51:20Z |
Issues and controversies of hepatocellular carcinoma-targeted therapy clinical trials in Asia: Experts'opinion
|
Yeo W.; Yeoh E.-M.; Furuse J.; Han K.-H.; Chiun Hsu; Lim H.-Y.; Moon H.; Qin S.; Ye S.-L.; Chen P.-J.; Chen P.-J.;Furuse J.;Han K.-H.;Chiun Hsu;Lim H.-Y.;Moon H.;Qin S.;Ye S.-L.;Yeoh E.-M.;Yeo W. |
| 臺大學術典藏 |
2020-04-10T12:51:20Z |
Efficacy and tolerability of bevacizumab plus capecitabine as first-line therapy in patients with advanced hepatocellular carcinoma
|
Hsu C.-H.;Yang T.-S.;Chiun Hsu;Toh H.C.;Epstein R.J.;Hsiao L.-T.;Chen P.-J.;Lin Z.-Z.;Chao T.-Y.;Cheng A.-L.; Hsu C.-H.; Yang T.-S.; Chiun Hsu; Toh H.C.; Epstein R.J.; Hsiao L.-T.; Chen P.-J.; Lin Z.-Z.; Chao T.-Y.; Cheng A.-L. |
| 臺大學術典藏 |
2020-04-10T12:51:20Z |
Bortezomib suppresses focal adhesion kinase expression via interrupting nuclear factor-kappa B
|
Ko B.-S.;Chang T.-C.;Chen C.-H.;Liu C.-C.;Kuo C.-C.;Chiun Hsu;Shen Y.-C.;Shen T.-L.;Golubovskaya V.M.;Chang C.-C.;Shyue S.-K.;Liou J.-Y.; Ko B.-S.; Chang T.-C.; Chen C.-H.; Liu C.-C.; Kuo C.-C.; Chiun Hsu; Shen Y.-C.; Shen T.-L.; Golubovskaya V.M.; Chang C.-C.; Shyue S.-K.; Liou J.-Y. |
| 臺大學術典藏 |
2020-04-10T12:51:19Z |
Phase II study of combining sorafenib with metronomic tegafur/uracil for advanced hepatocellular carcinoma
|
Hsu C.-H.;Shen Y.-C.;Lin Z.-Z.;Chen P.-J.;Shao Y.-Y.;Ding Y.-H.;Chiun Hsu;Cheng A.-L.; Hsu C.-H.; Shen Y.-C.; Lin Z.-Z.; Chen P.-J.; Shao Y.-Y.; Ding Y.-H.; Chiun Hsu; Cheng A.-L. |
| 臺大學術典藏 |
2020-04-10T12:51:18Z |
Clinical Development and Future Direction for the Treatment of Hepatocellular Carcinoma
|
Whang-Peng J.;Cheng A.-L.;Chiun Hsu;Chen C.-M.; Whang-Peng J.; Cheng A.-L.; Chiun Hsu; Chen C.-M. |
| 臺大學術典藏 |
2020-04-10T12:51:18Z |
Adjuvant interferon therapy after curative therapy for hepatocellular carcinoma (HCC): A meta-regression approach
|
Cheng A.-L.; Hu F.-C.; Cheng C.-C.; Chen L.-T.; Chiun Hsu; Shen Y.-C.; Shen Y.-C.;Chiun Hsu;Chen L.-T.;Cheng C.-C.;Hu F.-C.;Cheng A.-L. |
| 臺大學術典藏 |
2020-04-10T12:51:18Z |
Geographic difference in survival outcome for advanced hepatocellular carcinoma: Implications on future clinical trial design
|
Chiun Hsu; Shen Y.-C.; Cheng C.-C.; Hu F.-C.; Cheng A.-L.; Chiun Hsu;Shen Y.-C.;Cheng C.-C.;Hu F.-C.;Cheng A.-L. |
